How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease
Alzheimers Dement
.
2021 Jun;17(6):917-919.
doi: 10.1002/alz.12374.
Authors
Anna G M Temp
1
2
,
Michael W Lutz
3
,
Dominic Trepel
4
5
6
,
Yi Tang
7
,
Eric-Jan Wagenmakers
8
,
Ara S Khachaturian
9
,
Stefan Teipel
10
Affiliations
1
Clinical Research Section, German Centre for Neurodegenerative Diseases (DZNE), Rostock, Germany.
2
Translational Neurodegeneration Section "Albrecht Kossel,", Department of Neurology, University of Rostock, Rostock, Germany.
3
Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
4
School of Medicine, Trinity College Dublin, Dublin, Ireland.
5
Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.
6
University California San Francisco, San Francisco, USA.
7
Department of Neurology, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, China.
8
Department of Psychological Methods, University of Amsterdam, Amsterdam, the Netherlands.
9
Alzheimer's & Dementia: The Journal of the Alzheimer's Association, Rockville, Maryland, USA.
10
Department of Psychosomatic Medicine, University Medicine Rostock, Rostock, Germany.
PMID:
34115436
DOI:
10.1002/alz.12374
No abstract available
Publication types
Editorial
MeSH terms
Alzheimer Disease*
Clinical Trials as Topic
Data Interpretation, Statistical*
Humans
Models, Statistical*
Research Design*